CLINICAL TRIALS PROFILE FOR MUCINEX DM
✉ Email this page to a colleague
505(b)(2) Clinical Trials for MUCINEX DM
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00902707 ↗ | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | Reckitt Benckiser Inc. | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| OTC | NCT00902707 ↗ | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | Reckitt Benckiser LLC | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| OTC | NCT00902707 ↗ | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | University of North Carolina, Chapel Hill | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| OTC | NCT01114581 ↗ | Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection | Completed | Reckitt Benckiser LLC | Phase 2 | 2010-04-01 | The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for MUCINEX DM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00441246 ↗ | Phase 4 Study - Mucinex D as Adjunct Therapy | Completed | Adams Respiratory Therapeutics | Phase 4 | 2007-02-01 | The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection. |
| NCT00902707 ↗ | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | Reckitt Benckiser Inc. | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| NCT00902707 ↗ | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | Reckitt Benckiser LLC | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| NCT00902707 ↗ | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | University of North Carolina, Chapel Hill | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| NCT01046136 ↗ | Mucinex Exploratory Cold Study | Completed | Reckitt Benckiser Inc. | Phase 2 | 2009-12-01 | This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MUCINEX DM
Condition Name
Clinical Trial Locations for MUCINEX DM
Trials by Country
Clinical Trial Progress for MUCINEX DM
Clinical Trial Phase
Clinical Trial Sponsors for MUCINEX DM
Sponsor Name
